復(fù)溶 |
1.Epithelial-mesenchymal transition-like events in vulvar cancer and its relation with HPV.Rodrigues IS, Lavorato-Rocha AM, de M Maia B, Stiepcich MM, de Carvalho FM, Baiocchi G, Soares FA, Rocha RMBr J Cancer. 2013 Jul 9;109(1):184-94. doi: 10.1038/bjc.2013.273. Epub 2013 Jun 18.2.Twist2 is a valuable prognostic biomarker for colorectal cancer.Yu H, Jin GZ, Liu K, Dong H, Yu H, Duan JC, Li Z, Dong W, Cong WM, Yang JHWorld J Gastroenterol. 2013 Apr 21;19(15):2404-11. doi: 10.3748/wjg.v19.i15.2404.3.Significance of heterogeneous twist2 expression in human breast cancers.Mao Y, Zhang N, Xu J, Ding Z, Zong R, Liu Z.PLoS One. 2012;7(10):e48178. doi: 10.1371/journal.pone.0048178. Epub 2012 Oct 25.4.Discordant Gene Expression Signatures and Related Phenotypic Differences in Lamin A-and A/C-Related Hutchinson-Gilford Progeria Syndrome (HGPS).Plasilova M, Chattopadhyay C, Ghosh A, Wenzel F, Demougin P, Noppen C, Schaub N, Szinnai G, Terracciano L, Heinimann K.PLoS One. 2011;6(6):e21433. Epub 2011 Jun 27.5.Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal transition and cancer stem-like cell self-renewal.Fang X, Cai Y, Liu J, Wang Z, Wu Q, Zhang Z, Yang CJ, Yuan L, Ouyang G.Oncogene. 2011 May 23. [Epub ahead of print]6.Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus.Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, Fabien N, Cochat P, Pouteil-Noble C, Trolliet P, Durieu I, Tebib J, Kassai B, Ansieau S, Puisieux A, Eliaou JF, Bonnefoy-Berard N.Nat Immunol. 2009 Jul;10(7):778-85. Epub 2009 May 31.7.Molecular mechanism of transforming growth factor-beta-mediated inhibition of growth arrest and differentiation in a myoblast cell line.Murakami M, Ohkuma M, Nakamura M.Dev Growth Differ. 2008 Feb;50(2):121-30.
|